Senzime tar in kapital för fortsatt kommersiell expansion

Medtechbolaget Senzime har beslutat att genomföra en riktad nyemisson. Bolaget planerar att ta in cirka 86 miljoner kronor.

CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”

When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, abou...

Björn Ursing: Physicians new role in AI driven healthcare

”AI could be the key we need for tomorrow’s healthcare, but it is not a stand-alone tool”, writes Björn Ursing in a column about how the role for physicians cha...

Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation

A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure that new medicines will be available for all citizens in Europe, writes Marie Gårdmark...

Lucy Robertshaw: Are we in the perfect storm?

“Is there a perfect storm on the horizon again as elective surgeries were cancelled due to patients being admitted with Covid-19? We now have a long backlog of ...

Samuel Lagercrantz: Immunotherapy against cancer is still in its early stages

For more than 100 years, researchers have tried to target the body’s own immune system to fight cancer cells. They have occasionally been laughed at and ridicul...

Elicera develops CAR-T against solid tumours – may become the first in the world

in that field as well. “It is the largest field, and the potential is enormous,” says the company’s CEO Jamal El-Mosleh.

TCO easy comparison of electric and pneumatic solutions

Find the right technology for your application and compare CO₂ emission and TCO The shown results are not based on a sizing calculation, parameters like service...

Study: An objective diagnosis of constant tinnitus may be possible

A new method that measures brain activity during sound stimulation can make it possible to objectively diagnose and identify people who suffer from constant tin...

Column: "Are we already living in the new normal?"

2020 felt like the year that we were building the house around us whilst moving into it at the same time.

Raise-In AB

The Swedish Foundation for Strategic Research

Stockholm aims at becoming one of the world’s top life science regions

Regional Chair for Finance, Irene Svenonius (M), believes that Stockholm can realise the goal of becoming one of the world’s top 5 regions in life science by 20...

MSD i storaffär – köper rättigheter till hjärt-kärlkandidat

Merck & Co, känt som MSD utanför USA och Kanada, har ingått ett exklusivt licensavtal med kinesiska Hengrui Pharma. Avtalet rör rättigheterna till läkemedelskan...

Fyra pilotprojekt utvalda i life science-satsning

Bridge Sweden, projektet som går ut på underlätta identifiering och produktion av nya läkemedel, har valt ut sina första projekt.

Vicore tar in 782 miljoner för sin lungfibroskandidat

Vicore Pharma har beslutat att ta in upp till 782 miljoner kronor i en företrädesemission för att finansiera fortsatt utveckling av bolagets behandling för idio...

Try arivis for free

30-day free trial offers a number of benefits.

Astra Zenecas nya viktminskningsbolag ska bevara muskelmassa

Astra Zeneca har fullföljt en option att köpa det schweiziska start up-bolaget Sixpeaks Bio, som utvecklar fetmabehandlingar.

Recipharm ingår samarbete med global koncern

Recipharm ingår ett strategiskt samarbete med den globala franska koncernen Product Life Group (PLG).

Exakt tryckreglering med Tescom – när precision är avgörande

OEM Automatic erbjuder ett brett sortiment av tryckregulatorer från Tescom – anpassade för att möta höga krav inom allt från gasleveranssystem till avancerad in...

A new international stem cell research centre has been created in Copenhagen

A new centre for stem cell research opened to the public in January. The Novo Nordisk Foundation backs the initiative with the ambition that the centre will advance new medical technology and ...

Framgång för Hansa i amerikansk fas III-studie – ”Vi är begeistrade”

Lundbaserade Hansa Biopharmas transplantationsläkemedel imlifidase klarade det primära effektmåttet i en registreringsgrundande fas III-studie i USA.

Medical plastics insights at Röchling

An exclusive look behind the scenes.

Sanofi ingår samarbete om radiofarmaka – investerar miljardbelopp

Franska läkemedelsföretaget Sanofi och Orano Med har ingått ett avtal om utvecklingen av radioligand-terapier. Sanofi investerar samtidigt 300 miljoner euro i b...